Don’t miss the latest developments in business and finance.

Shilpa Biologicals files first Drug Master File of recombinant Human Albumin 20% with USFDA

Image
Last Updated : Jun 04 2024 | 6:31 PM IST
Shilpa Biologicals, a wholly owned subsidiary of Shilpa Medicare has filed its first Drug Master File of recombinant Human Albumin 20% with USFDA.

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive.

Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jun 04 2024 | 6:10 PM IST

Next Story